VEGFA and glioblastoma: The observation that lesions that are more likely to obtain a survival advantage from anti-VEGF (high-ADCL lesions) exhibit lower rCBV is consistent with prior studies demonstrating a favorable prognostic value of low rCBV in recurrent glioblastomas treated with anti-VEGF therapy [42-44].